Regulatory B Cells

A special issue of Antibodies (ISSN 2073-4468).

Deadline for manuscript submissions: closed (30 June 2019) | Viewed by 6354

Special Issue Editor


E-Mail Website
Guest Editor
Department of Immunology, Eötvös Loránd University, 1117 Budapest, Hungary
Interests: regulation of the humoral immune response; the “crosstalk” between receptors expressed on B lymphocytes; B cell signaling; autoimmunity; rheumatoid arthritis; cooperation between regulatory B cells and T cell subsets
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Besides antigen presentation and antibody production, B cells also play an important role in immune regulation by producing both pro-inflammatory (IL-6, TNF) and anti-inflammatory (IL-10, TGFβ) cytokines. A variety of B cell subsets have been identified as regulatory B cells (Bregs) on the basis of their suppressive function, although no specific marker or transcription factor have been identified. Inflammation provoked by microbes or dying cells may induce the development of Bregs.  Breg cells can suppress the immune response by blocking antigen presentation by dendritic cells, inhibiting proliferation and cytokine production by helper T cells, while stimulating the differentiation of regulatory T cells (Tregs). Bregs suppress the inflammatory response by multiple mechanisms, including the secretion of IL-10 and TGFβ, direct cell–cell contact, expression of PD-L1 or FasL.

A lot of work has been conducted to identify Bregs, characterize the signals inducing them, and reveal the regulatory mechanisms involved; however, open questions still remain on the origin of Bregs and on the way they are induced and regulated. Breg cells have been extensively studied in autoimmune diseases and allergy, and emerging evidence suggests that Bregs are pivotal in inducing tolerance in kidney transplantation and a play a protective role in neuroinflammation and experimental stroke. However, tumor-induced Breg cells may promote tumor cell growth.

Thus, although Bregs are crucial players in several immune-mediated disorders, and potential Breg-targeted therapies have been suggested, we have much more to learn about immune response regulation by Bregs before developing Breg-based immunotherapies. 

We expect contributions to this Special Issue including recent research on the induction and control of Breg cells, cellular interactions and regulatory mechanisms of Bregs, and their potential therapeutic applications.

Prof. Dr. Gabriella Sármay
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Antibodies is an international peer-reviewed open access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • B lymphocyte
  • Regulatory B cells
  • Immunotherapies
  • Cellular therapies
  • Breg targeting
  • Autoimmune diseases
  • Inflammation
  • Immunoregulation
  • Tolerance induction

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

12 pages, 2337 KiB  
Communication
NR4A Expression by Human Marginal Zone B-Cells
by Kim Doyon-Laliberté, Josiane Chagnon-Choquet, Michelle Byrns, Matheus Aranguren, Meriam Memmi, Pavel Chrobak, John Stagg, Johanne Poudrier and Michel Roger
Antibodies 2019, 8(4), 50; https://doi.org/10.3390/antib8040050 - 11 Oct 2019
Cited by 8 | Viewed by 5891
Abstract
We have previously characterized a human blood CD19+CD1c+IgM+CD27+CD21loCD10+ innate-like B-cell population, which presents features shared by both transitional immature and marginal zone (MZ) B-cells, named herein “precursor-like” MZ B-cells. B-cells with similar [...] Read more.
We have previously characterized a human blood CD19+CD1c+IgM+CD27+CD21loCD10+ innate-like B-cell population, which presents features shared by both transitional immature and marginal zone (MZ) B-cells, named herein “precursor-like” MZ B-cells. B-cells with similar attributes have been associated with regulatory potential (Breg). In order to clarify this issue and better characterize this population, we have proceeded to RNA-Seq transcriptome profiling of mature MZ and precursor-like MZ B-cells taken from the blood of healthy donors. We report that ex vivo mature MZ and precursor-like MZ B-cells express transcripts for the immunoregulatory marker CD83 and nuclear receptors NR4A1, 2, and 3, known to be associated with T-cell regulatory (Treg) maintenance and function. Breg associated markers such as CD39 and CD73 were also expressed by both populations. We also show that human blood and tonsillar precursor-like MZ B-cells were the main B-cell population to express elevated levels of CD83 and NR4A1-3 proteins ex vivo and without stimulation. Sorted tonsillar precursor-like MZ B-cells exerted regulatory activity on autologous activated CD4+ T-cells, and this was affected by a CD83 blocking reagent. We believe these observations shed light on the Breg potential of MZ populations, and identify NR4A1-3 as potential Breg markers, which as for Tregs, may be involved in stabilization of a regulatory status. Since expression and activity of these molecules can be modulated therapeutically, our findings may be useful in strategies aiming at modulation of Breg responses. Full article
(This article belongs to the Special Issue Regulatory B Cells)
Show Figures

Figure 1

Back to TopTop